BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - EPA:BLC - FR0000035370 - Common Stock
25.3 EUR
-0.8 (-3.07%)
Overall BLC gets a fundamental rating of 4 out of 10. We evaluated BLC against 31 industry peers in the Health Care Providers & Services industry. BLC has only an average score on both its financial health and profitability. BLC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
In the past year BLC had a positive cash flow from operations.
Of the past 5 years BLC 4 years were profitable.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 0.08%, BLC is not doing good in the industry: 77.42% of the companies in the same industry are doing better.
BLC has a Return On Equity of 0.73%. This is in the lower half of the industry: BLC underperforms 70.97% of its industry peers.
BLC's Return On Invested Capital of 6.40% is fine compared to the rest of the industry. BLC outperforms 61.29% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 6.75%.
The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.40%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROIC | 6.4% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
The Profit Margin of BLC (0.11%) is worse than 77.42% of its industry peers.
In the last couple of years the Profit Margin of BLC has declined.
With a decent Operating Margin value of 8.17%, BLC is doing good in the industry, outperforming 64.52% of the companies in the same industry.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
BLC has a better Gross Margin (67.80%) than 74.19% of its industry peers.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BLC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, BLC has about the same amount of shares outstanding.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
BLC has an Altman-Z score of 1.40. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
BLC has a Altman-Z score (1.40) which is in line with its industry peers.
The Debt to FCF ratio of BLC is 12.90, which is on the high side as it means it would take BLC, 12.90 years of fcf income to pay off all of its debts.
BLC's Debt to FCF ratio of 12.90 is in line compared to the rest of the industry. BLC outperforms 45.16% of its industry peers.
A Debt/Equity ratio of 5.29 is on the high side and indicates that BLC has dependencies on debt financing.
BLC's Debt to Equity ratio of 5.29 is on the low side compared to the rest of the industry. BLC is outperformed by 87.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.4 |
ROIC/WACC1.26
WACC5.07%
2.3 Liquidity
BLC has a Current Ratio of 1.38. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.38, BLC is doing good in the industry, outperforming 70.97% of the companies in the same industry.
BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.18, BLC is in the better half of the industry, outperforming 74.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
The Revenue has been growing slightly by 6.35% in the past year.
BLC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.12% yearly.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.22% yearly.
BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y9.77%
Revenue Next 5Y7.69%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 361.43, BLC can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BLC is valued a bit more expensive than 77.42% of the companies in the same industry.
BLC is valuated expensively when we compare the Price/Earnings ratio to 25.46, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 9.26, the valuation of BLC can be described as reasonable.
Based on the Price/Forward Earnings ratio, BLC is valued cheaper than 93.55% of the companies in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 361.43 | ||
| Fwd PE | 9.26 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 90.32% of the companies listed in the same industry.
BLC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BLC is cheaper than 83.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.85 | ||
| EV/EBITDA | 5.74 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLC does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BLC's earnings are expected to grow with 16.22% in the coming years.
PEG (NY)8.68
PEG (5Y)N/A
EPS Next 2Y16.22%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (11/19/2025, 5:00:39 PM)
25.3
-0.8 (-3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap186.46M
Revenue(TTM)491.18M
Net Income(TTM)528.00K
Analysts83.33
Price Target36.72 (45.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.84%
EPS NY rev (3m)-20.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2%
Revenue NY rev (3m)-14.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 361.43 | ||
| Fwd PE | 9.26 | ||
| P/S | 0.38 | ||
| P/FCF | 5.85 | ||
| P/OCF | 2.03 | ||
| P/B | 2.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.74 |
EPS(TTM)0.07
EY0.28%
EPS(NY)2.73
Fwd EY10.8%
FCF(TTM)4.32
FCFY17.09%
OCF(TTM)12.48
OCFY49.32%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)8.68
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROCE | 8.71% | ||
| ROIC | 6.4% | ||
| ROICexc | 6.78% | ||
| ROICexgc | 12.12% | ||
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.79 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.25% | ||
| Profit Quality | 6036.93% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.4 |
F-Score8
WACC5.07%
ROIC/WACC1.26
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y9.77%
Revenue Next 5Y7.69%
EBIT growth 1Y18.25%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year133.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 361.43 and the Price/Book (PB) ratio is 2.58.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.77%.